Leukemia, Myeloid, Acute Clinical Trials

25 recruiting

Leukemia, Myeloid, Acute Trials at a Glance

26 actively recruiting trials for leukemia, myeloid, acute are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in New York, Winston-Salem, and Los Angeles. Lead sponsors running leukemia, myeloid, acute studies include Janssen Research & Development, LLC, The First Affiliated Hospital of Xiamen University, and BlossomHill Therapeutics.

Browse leukemia, myeloid, acute trials by phase

Treatments under study

About Leukemia, Myeloid, Acute Clinical Trials

Looking for clinical trials for Leukemia, Myeloid, Acute? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukemia, Myeloid, Acute trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukemia, Myeloid, Acute clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 2

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic SyndromesMixed Phenotype Acute LeukemiaLeukemia, Myeloid, Acute
Orca Biosystems, Inc.80 enrolled5 locationsNCT07216443
Recruiting
Phase 1Phase 2

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

Leukemia, Myeloid, Acute
Miltenyi Biomedicine GmbH29 enrolled1 locationNCT06424340
Recruiting
Phase 1

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 1

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC115 enrolled9 locationsNCT06618001
Recruiting
Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled239 locationsNCT06852222
Recruiting
Phase 1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC155 enrolled9 locationsNCT06651229
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Leukemia, Myeloid, Acute
Wake Forest University Health Sciences50 enrolled2 locationsNCT06580106
Recruiting
Early Phase 1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Myelodysplastic Syndromes (MDS)Precursor Cell Lymphoblastic Leukemia-LymphomaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic18 enrolled1 locationNCT06765876
Recruiting
Phase 1Phase 2

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute
Zhujiang Hospital20 enrolled1 locationNCT05270200
Recruiting
Phase 1

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+3 more
BlossomHill Therapeutics170 enrolled13 locationsNCT06501196
Recruiting
Phase 2

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, AcuteRefractory LeukemiaRelapsed Adult AML
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT05305859
Recruiting
Phase 2

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Leukemia, Myeloid, Acute
OncoVerity, Inc.120 enrolled31 locationsNCT06384261
Recruiting
Phase 1Phase 2

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute
Delta-Fly Pharma, Inc.39 enrolled4 locationsNCT06382168
Recruiting
Phase 1Phase 2

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more
Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574
Recruiting
Phase 1

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

Leukemia, Myeloid, Acute
University of Pennsylvania16 enrolled1 locationNCT05945849
Recruiting

Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia

Myelodysplastic SyndromesLeukemia, Myeloid, Acute
Groupe Francophone des Myelodysplasies6,990 enrolled1 locationNCT06956755
Recruiting
Phase 1Phase 2

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute
Guangzhou Bio-gene Technology Co., Ltd24 enrolled3 locationsNCT06118788
Recruiting
Phase 2

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, AcuteAML Stage, Adult
The First Affiliated Hospital of Xiamen University66 enrolled1 locationNCT05603884
Recruiting
Not Applicable

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

Leukemia, Myeloid, AcuteMyeloid DysplasiaOvarian Epithelial Cancer
European Institute of Oncology157 enrolled1 locationNCT06785077